羊膜移植联合板层角膜移植术治疗蚕蚀性角膜溃疡

目的观察羊膜移植联合板层角膜移植术治疗蚕蚀性角膜溃疡的临床效果。方法采用羊膜移植联合板层角膜移植术治疗蚕蚀性角膜溃疡患者15例(16眼),术后辅以地塞米松及环孢霉素A眼液局部治疗,观察羊膜植片生长情况、视力及病情有无复发。术后随访10～18(平均12)月。结果15例(16眼)蚕蚀性角膜溃疡患者术后均未见角膜病变复发,羊膜植片生长良好,未见脱落及溶解,无新生血管长入,视力有不同程度的提高。结论羊膜移植联合板层角膜移植术可有效治疗蚕蚀性角膜溃疡,防止病变复发。     

湟鱼角膜移植治疗单疱病毒性角膜溃疡临床研究

目的:探讨湟鱼角膜板层移植联合术后10g/L环孢霉素A滴眼治疗单疱病毒性角膜溃疡的效果及对视力的影响。方法:采用湟鱼角膜板层移植治疗单疱角膜溃疡46例57眼。术中切除病变的角膜组织,根据植床的形态制作相应的板层移植片。术后应用10g/L环孢霉素A眼液滴眼3～6mo。结果:术后随访10～13a未见复发病例。术后1a与术前视力比较,大部分病例视力提高。结论:异种异体板层角膜移植术治疗单疱角膜溃疡术后应用10g/L环孢霉素A滴眼液远期效果肯定。溃疡面充分愈合,移植片透明,不影响视力。     

蚕蚀性角膜溃疡的临床特点分析

探讨蚕蚀性角膜溃疡患者的临床特点和比较治疗方法的效果。方法对连续治疗的蚕蚀性角膜溃疡患者５５０例的患病年龄,性别,眼别,溃疡部位,溃疡穿孔,溃疡复发情况,以及球结膜切除术,板层角膜移植术及板层角膜移植术联环孢霉素Ａ滴眼的疗效进行分析情况,以及球结膜切除术,板层角膜移植术及板层角膜术联合环孢霉素Ａ滴眼的疗效进行分析。结果平均患病年龄４８．４岁;男：女之比为１：０．７４;双眼患病者１６５例,其中青年患     

蚕蚀性角膜溃疡的综合治疗

目的:探讨蚕蚀性角膜溃疡的最佳有效治疗方案。方法:将连续治疗的蚕蚀性角膜溃疡患者54例(77眼),按治疗方案的不同分为3组,单纯角膜溃疡切除联合板层角膜移植组21眼,角膜溃疡及邻近球结膜切除联合板层角膜移植组19眼,板层角膜移植术后联合应用地塞米松、环孢霉素A组37眼,对其疗效进行回顾性分析。结果:单纯角膜溃疡切除联合板层角膜移植术组一次性手术治愈率为48%,复发率为33%。角膜溃疡联合临近球结膜切除板层角膜移植术组一次性手术治愈率为68%,复发率为26%。板层角膜移植联合应用免疫抑制剂组一次性治愈率为76%,复发率为24%。结论:角膜溃疡及邻近球结膜切除联合板层角膜移植术后应用地塞米松及环孢霉素A眼液是目前治疗蚕蚀性角膜溃疡的最佳有效方法。     

个体化板层角膜移植治疗蚕蚀性角膜溃疡

目的探讨依据蚕蚀性角膜溃疡病变形态施行不同形状的个体化板层角膜移植治疗的疗效。方法回顾性系列病例研究。2008年1月至2011年6月中山眼科中心确诊的蚕蚀性角膜溃疡患者26例（31眼）,根据溃疡累及周边部角膜范围和形态选择不同手术方式,分为新月形板层角膜移植组（14眼）、D形板层角膜移植组（7眼）、指环型板层角膜移植组（3眼）和全板层角膜移植组（7眼）。术后随访6～36个月,评价患者术后视力、植片透明性、角膜散光变化规律以及并发症发生种类。结果术后6个月最佳矫正视力为0．3～0．5的患者中,新月形板层角膜移植组3例,D形板层角膜移植组4例．全板层角膜组5例：最佳矫正视力为0．6～1．0患者新月形板层角膜移植组11例．D形板层角膜移植组3例,指环形板层角膜移植组3例,全板层角膜移植组2例。术后视力提高患者比例为54％,视力不变比例为40％,视力下降比例为6％。术后6个月指环形板层角膜移植组角膜散光最低,为（2．30＋0．40）D：D形板层角膜移植组散光最高,为（3．70＋1．03）D。术后主要并发症为植片上皮愈合不良4例（13％）,蚕蚀性角膜溃疡复发2例（6％）,缝线脓肿1例（3％）,植片排斥4例（13％）。结论依据蚕蚀性角膜溃疡累及周边部角膜的部位和形态施行不同形状的板层角膜移植,可以在切除病灶的同时避免正常角膜组织的损失,减轻角膜散光程度,恢复患者的有效视力。     

大植片板层角膜移植治疗重症蚕蚀性角膜溃疡

目的:探讨大植片板层角膜移植重建角膜基质和眼表结构治疗重症蚕蚀性角膜溃疡的疗效。方法:对6例(9眼)术前药物及其他手术治疗无效、病变区累及角膜1/2以上的重症蚕蚀性角膜溃疡的患者,在保留正常角膜后弹力层的基础上,彻底清除病灶,并采用带角膜缘干细胞的大植片板层角膜移植。术后予以10g/L环胞霉素A+皮质类固醇眼液滴眼。结果:术后9眼刺激症状缓解,角巩膜创面光滑,角膜植片透明,愈合良好,视力逐渐提高。经过平均20.6mo随访,眼表保持稳定,未见溃疡复发,除角膜层间新生血管及上皮型排斥反应外,未出现明显并发症。结论:采用新鲜的带环形巩膜瓣的全角膜板层移植术,配合术后长期应用皮质类固醇和免疫抑制剂,是目前治疗复发性蚕蚀性角膜溃疡最有效的手术方法。     

不同受者同期分别接受同者的角膜移植五例

目的 为提高角膜材料的利用率,探讨将同一噶供者的二个角膜同期移植给不同受者的可行性及手术方法.方法 供者的其中一个角膜材料分别为1例角结膜恶性黑色素瘤,1例蚕蚀性角膜溃疡伴穿孔行前部分板层角膜移植术,并对1例大泡性角膜病变行深板层角膜内皮移植术.另一个角膜材料分别为眼烧伤后重度睑球粘连行全板层角膜移植和1例大泡性角膜病变行深板层角膜内皮移植术.结果 5例角膜病患者手术均获得成功,其中2例大泡性角膜病变患者术后1个月,角膜上皮水泡消失,角膜水肿减轻,内皮植片透明.1例角结膜恶性黑色素瘤患者,视力术前0.3提高至术后0.6,植片透明,角膜植床及结膜无色素残留.1例蚕蚀性角膜伴穿孔经羊膜移植联合部分板层角膜移植治愈.1例眼烧伤睑球粘连患者,术后1个月,睑球粘连完全解除,植片透明,视力由术前0.1提高到0.3.结论 将同一供者的角膜分别移植给不同受者,能充分利用供者角膜材料,方法可行,效果良好.     

深板层角膜移植治疗角膜病的临床观察

目的：评价深板层角膜移植治疗角膜病的效果。

方法：回顾行深板层角膜移植术患者5例6眼。使用新鲜同种异体角膜3例,进行角膜巩膜缘的大植片移植,用于蚕蚀性角膜溃疡1例2眼,边缘性角膜变性1例1眼。使用保存角膜3例,进行单纯前部深板层角膜移植,用于单疱病毒性角膜炎后角膜深层斑翳2例2眼,角膜皮样瘤1例1眼。术后随访18mo,观察术后视力、植片透明度和术后并发症情况。

结果：术前视力：HM/眼前～0.06。随访5眼最佳矫正视力明显提高(0.2～0.5),1眼植片中度混浊,视力(0.05)稍有提高。

结论：深板层角膜移植治疗角膜病具有较好疗效,容易在基层医院开展。     

多来源角膜植片用于治疗性角膜移植

目的 探讨多种来源的角膜植片在治疗性角膜移植的临床价值。方法 应用因眼外伤和青光眼摘除眼球的角膜、胎儿角膜、捐献或死囚角膜以及眼库提供角膜28只眼施行治疗性板层（包括反角膜板层）或穿透性角膜移植或加羊膜移植共30眼,结果 感染性角膜溃疡22眼（真菌性12眼）中19眼术后感染控制,保全了眼球,12眼视力不同程度提高。8眼蚕蚀性角膜溃疡、角膜热烧伤、角膜白斑和角膜边缘变性近穿孔都获得健全的眼表,视力提高植片透明5眼。结论 寻找多个渠道获取角膜植片进行治疗性角膜移植,效果确切,可在一定程度缓解角膜材料的紧缺状态,对抢救近穿孔的感染性角膜溃疡,具有重要意义。     

环孢霉素A在高危角膜移植免疫排斥应用观察

目的：探讨环孢霉素A在高危角膜移植手术后防治角膜移植排斥反应的疗效。方法：对在我院施行穿透性及槔层角膜移植术中属于高危角膜移植的病共24例26只眼,其中≥9mm的大植片的有12只眼（占50％）,在术后26只眼均用环孢霉素A口服及环孢霉素A液滴眼。结果：角膜移植术后出现角膜排斥反应的有10例11只眼（占42．3％）,经过治疗后角膜植片均透明,术后角膜移植片最终透明者有24只眼（占92．3％）,未见严重副作用。结论：证明在高危角膜移植术应用环孢霉素A治疗角膜移排斥反应是确实有效。     

部分环状板层角膜移植治疗蚕蚀性角膜溃疡

目的 观察部分环状板层角膜移植治疗早期药物治疗无效的进展性蚕蚀性角膜溃疡的临床疗效.方法 回顾性系列病例研究.10例(11眼)常规给予局部及全身免疫抑制剂和对症治疗1周及以上、病灶不断扩散的蚕蚀性角膜溃疡患者,行部分环状板层角膜移植手术,角膜供体选自部分穿透性角膜移植术后残留的环形供体角膜.手术方法:采用7.75～8.00 mm的环钻在角膜中央压痕,在彻底切除病灶后,覆盖与病灶范围相同的供体角膜.随访6～36个月,观察患者的视力、角膜植片愈合时间及是否复发等.采用重复测量方差分析比较手术前后视力变化.结果 患者裸眼视力术后1个月平均提高(1.36±1.21)行,术后3个月平均提高(1.72±1.47)行,术后6个月平均提高(1.86±2.04)行;最佳矫正视力术后1个月平均提高(0.46±0.93)行,术后3个月平均提高(0.73±1.10)行,术后6个月平均提高(1.55±1.75)行.手术前后裸眼视力(F=5.630,P＜0.05)与最佳矫正视力(F=5.925,P＜0.05)差异均有统计学意义.术后患者角膜植片上皮平均愈合时间为(7.00±5.31)d;1例患者术后角膜植片上皮愈合不良,行羊膜移植术后20 d愈合;1例患者术后19个月复发,行二次部分板层角膜移植.所有患者随访期间未发生免疫排斥反应等并发症.结论 使用环形供体角膜的部分板层角膜移植能有效控制早期药物治疗无效的蚕蚀性角膜溃疡的发展,保存视轴区透明角膜,术后视觉效果良好,同时节约角膜供体材料.     

Effect of FK506 eye-drop combined with keratoplasty on recurrent Mooren's ulcer

OBJECTIVE: To observe the effect of FK506 eye-drop combined with keratoplasty on recurrent Mooren's ulcer. METHODS: 9 cases (15 eyes) of recurrent Mooren's ulcer were treated with topical FK506 eye-drop combined with keratoplasty. Of the 15 eyes, two of Mooren's ulcer smaller than half circle of the limbus were treated with 0.1% FK506 eye-drop. Among the other 13 eyes of the ulcer larger than half the circle of the limbus, 12 eyes were treated with excision of conjunctiva combined with lamellar keratoplasty. One eye with a central corneal perforation was treated with penetrating keratoplasty. FK506 eye-drop 0.1% was given to the 13 operated eyes after the re-epithelialization of the cornea. The effect of FK506 on recurrent Mooren's ulcer was observed. Measurements of FK506 in surgically resected cornea and conjunctiva, and aqueous humor of the operated eyes were performed using enzyme immunoassay procedure. Twelve cases of recurrent Mooren's ulcer treated with lamellar keratoplasty combined with topical 0.1% dexamethasone eye-drop were taken as control. RESULTS: After application of 0.1% FK506 eye-drop, concentrations of 30 - 350 ng/g of FK506 were found in the cornea and conjunctiva, and no FK506 was measured in the aqueous humor. Nine cases (15 eyes) of recurrent Mooren's ulcer were all cured and no recurrence was observed during the follow-up time of 12 - 17 months. The vision of 5 eyes was improved more than 2 lines after the treatment. Seven eyes of Mooren's ulcer in the control group recurred. CONCLUSION: 0.1% FK506 eye-drop combined with keratoplasty is an effective treatment for recurrent Mooren's ulcer.     

带环形巩膜瓣及角膜缘的全角膜板层移植术治疗蚕蚀性角膜溃疡

目的观察带环形巩膜瓣及角膜缘的全角膜板层移植术治疗蚕蚀性角膜溃疡的临床效果.方法取带宽6mm球结膜和4mm板层巩膜的全角膜板层植片,治疗4例(4只眼)蚕蚀性角膜溃疡.结果 4例蚕蚀性角膜溃疡患者均Ⅰ期愈合,视力提高;随访1～3年,视力为0.2～0.6,无明显基质型排斥反应,也无复发;角膜表面稳定,无上皮糜烂现象,无假性翼状胬肉发生;层间新生血管部分萎缩,2例表层出现不同程度的新生血管.结论带环形巩膜瓣及角膜缘的全角膜板层移植术是治疗蚕蚀性角膜溃疡的有效手段.     

Recurrence of Mooren's ulcer after lamellar keratoplasty

A 45-year-old man with unilateral Mooren's ulcer in a quiescent state underwent annular lamellar keratoplasty after corneal rupture due to minor trauma. Postoperatively, he did well until 8 months later when a recurrence of the Mooren's ulceration occurred, involving the central island of the patient's original corneal stroma. The stroma of the lamellar graft was uninvolved. This unusual occurrence lends support to the concept that there is a specific immunologic reaction to the cornea in patients with Mooren's ulcer.     

穿透性角膜移植治疗重症真菌性角膜溃疡效果观察

目的探讨穿透性角膜移植治疗重症真菌性角膜溃疡的临床效果。方法对重症真菌性角膜溃疡10例(10眼)行穿透性角膜移植术,随访3~6月。结果术后10眼感染全部得到控制,8眼植片透明,1眼行二次穿透性角膜移植,术后角膜透明。术后视力均比术前提高。结论穿透性角膜移植治疗真菌性角膜溃疡可有效地控制感染,改善视功能,效果较好。     

A Study of Clinical Characteristics and Treatment of Mooren‘s Ulcer

Objective: To investigate the clinical characteristics and to compare the effects of several therapies of Mooren's corneal ulcer.Methods: 550 consecutive cases of Mooren's corneal ulcer inpatients were analysed, including the age, sex, laterality of the eye, ulcer location , perforative rate, cure rate of surgeries, recurrent rate, and the effects of conjunctiva excision, lamellar keratoplasty (LKP), LKP and plus cyclosporin A eye drop.Results: The average age of onset of the cornea! ulcer was 48.4 years old, the ratio of the male to the female patients was 1:0.74, the bilateral disease was 30% of the total cases, 31.5% of the bilateral disease occurred in the younger group, and 68.5% of the bilateral ulcer occurred in the older group, ulcers located at the limbus of the palpebral fissure were 70% of the total cases, perforative rate was 13.3% , 43.2% of the perforation occurred in the younger group, and 56.8% of the perforation occurred in the older group, recurrent rate of the post-opertion was 25.6%,     

Effect of Topical FK506 Used alone or Combined with Keratoplasty on Patients with Recurrent Mooren''''s Corneal Ulcer

PURPOSE: To evaluate the efficacy of topical 0.1% FK506 used alone or combined with keratoplasty on patients with recurrent Mooren's ulcer. METHODS: This is a retrospective interventional consecutive case series. Nine patients (15 eyes) with recurrent Mooren's ulcer were treated with topical 0.1% FK506 alone or combined with keratoplasty. Two eyes with ulcers involving less than half the corneal limbus were treated with topical 0.1% FK506. Of the other 13 eyes with ulcers involving more than half the limbus, twelve were treated with excision of the ulcer and adjacent conjunctiva combined with lamellar keratoplasty. One eye with a central impending corneal perforation was treated with penetrating keratoplasty. Topical 0.1% FK506 was given post-operatively to all thirteen eyes after re-epithelia-lisation of the cornea. FK506 levels in the surgically resected cornea and conjunctiva of the operated eyes were measured using enzyme immunoassay procedures. Twelve patients (17 eyes) with recurrent Mooren's ulcer treated with lamellar keratoplasty combined with topical 0.1% dexamethasone were taken as the control. The main measure of the outcome was the recurrence of Mooren's ulcer in the patients. RESULTS: Nine patients (15 eyes) with recurrent Mooren's ulcer were all successfully treated. Vision in 5 eyes improved by two lines or better after treatment. No recurrence was observed during the follow up period of 12 to 22 months. After topical application of 0.1% FK506, concentrations of 30 to approximately 350 ng/g of FK506 were found in the cornea and conjunctiva. Seven eyes of Mooren' s ulcer in the control group recurred during the follow up period. CONCLUSION: Topical 0.1% FK506 used alone or combined with keratoplasty is a safe and effective therapy for patients with recurrent Mooren's ulcer.